Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.

Authors

David M. Charytan
Jonathan Himmelfarb
T Alp Ikizler
Dominic S. Raj, George Washington University
Jesse Y. Hsu
J Richard Landis
Amanda H. Anderson
Adriana M Hung
Rajnish Mehrotra
Shailendra Sharma, George Washington University
Daniel E. Weiner
Mark Williams
Marcelo DiCarli
Hicham Skali
Paul L. Kimmel
Alan S. Kliger
Laura M. Dember
Hemodialysis Novel Therapies Consortium

Document Type

Journal Article

Publication Date

4-1-2019

Journal

Kidney International

Volume

95

Issue

4

Inclusive Pages

973-982

DOI

10.1016/j.kint.2018.08.034

Keywords

Adult; Aged; Aldosterone; Cardiovascular Diseases; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Doppler; Feasibility Studies; Female; Gynecomastia; Humans; Hyperkalemia; Hypotension; Kidney Failure, Chronic; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Placebos; Potassium; Renal Dialysis; Spironolactone

Comments

Epub 2018 Nov 23

APA Citation

Charytan, D. M., Himmelfarb, J., Ikizler, T., Raj, D. S., Hsu, J. Y., Landis, J., Anderson, A. H., Hung, A., Mehrotra, R., Sharma, S., Weiner, D. E., Williams, M., DiCarli, M., Skali, H., Kimmel, P. L., Kliger, A. S., Dember, L. M., & Therapies Consortium, H. (2019). Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.. Kidney International, 95 (4). http://dx.doi.org/10.1016/j.kint.2018.08.034

Peer Reviewed

1